AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Probi Regulatory Filings 2009

Oct 14, 2009

3099_rns_2009-10-14_5b0cabdf-5dbb-4082-b81f-2f03e2678407.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

PRESS RELEASE 2009-10-14, 10.00 (CET)

Market Maker agreement terminated

Probi has terminated its Market Maker agreement with HQ Bank. The agreement will cease on 2009- 12-31. A new market maker has not been appointed.

For further information, please contact:

Michael Oredsson, CEO Probi, phone. +46 46 286 89 23 or mobile +46 707 18 89 30, e-mail: [email protected]

About Probi

Probi is a leading player in the field of probiotic research and development of effective and well-documented probiotics. The research areas are: stomach and gastrointestinal tracts, immune defense, metabolic disorders as well as stress and recovery. Probi's customers are leading companies within the business areas Functional Food and Dietary Supplements. The company's total operating income was 69.4 million SEK 2008, consisting mostly of royalty revenues. Probi's shares are listed on the Nordic List of the Stockholm Stock Exchange, Small Cap and has approximately 4.000 shareholders. Visit www.probi.com.